ALL Panel (Cytogenetics + FISH [BCR/ABL, TEL/AML1, MLL, E2A]) in UAE | 2800 AED | 2026 DHA Guidelines

تحليل ALL Panel (Cytogenetics + FISH [BCR/ABL، TEL/AML1، MLL، E2A]) في الإمارات | 2800 درهم | معتمد من هيئة الصحة بدبي

Clinical Authority & Patient Trust: 99.9% diagnostic sensitivity achieved through ISO 9001:2015‑certified processing (Cert: INT/EGQ/2509DA/3139). Premium hospital‑grade home collection with immediate cold‑chain transport for bone marrow or peripheral blood. Post‑test telephonic guidance by consultant hematopathologists. Direct insurance billing verification via WhatsApp: +971 54 548 8731.

الملخص التنفيذي: دقة تشخيصية فائقة بنسبة 99.9% عبر مختبر معتمد وفق ISO 9001:2015. خدمة سحب منزلي فاخرة لنخاع العظم أو الدم المحيطي مع نقل فوري مبرد لضمان سلامة العينة. استشارة هاتفية بعد الفحص مع استشاري أمراض الدم لتفسير النتائج. التحقق المباشر من التغطية التأمينية عبر واتساب الرقم +971 54 548 8731.

Comprehensive Leukemia Cytogenetics Overview

The ALL Panel (Cytogenetics + FISH) integrates conventional karyotyping and targeted fluorescence in‑situ hybridization to detect the most clinically significant gene fusions in acute lymphoblastic leukemia. In the UAE, this panel delivers definitive risk stratification and therapy‑guiding insights, reported within 10 days, at a fixed price of 2800 AED under DHA‑compliant protocols.

تجمع لوحة ALL الشاملة بين التنميط النووي التقليدي وتهجين التألق الموضعي للكشف عن الاندماجات الجينية الحاسمة في سرطان الدم الليمفاوي الحاد، مما يوفر تصنيفًا دقيقًا للمخاطر وتوجيهًا علاجيًا في الإمارات خلال 10 أيام.

Parameter	Our ALL Panel	Closest Alternative (Conventional Karyotyping Alone)
Methodology	G‑banding Karyotyping + Multi‑probe FISH (BCR/ABL, TEL/AML1, MLL, E2A)	G‑banding Karyotyping only
Detection Rate	99.9% for targeted abnormalities; uncovers cryptic rearrangements invisible to karyotyping	~60–70% for gross chromosomal changes; misses clinically actionable cryptic fusions
Turnaround Time	10 working days (optimized culture + FISH workflow)	14–21 days
Clinical Utility	Comprehensive risk stratification, MRD surrogate, targeted therapy eligibility (e.g., TKI for BCR/ABL)	Basic ploidy‑based risk classification only; misses key driver fusions

Physician Insight & Safety Protocol

“As a hematopathologist, I recognize the emotional weight carried by patients and families facing a suspected leukemia diagnosis. This panel’s precision allows us to pinpoint critical genetic drivers so your oncologist can design the most personalized, effective treatment strategy. Nevertheless, these results must always be integrated with full clinical assessment and never taken in isolation.”

— Dr. PRABHAKAR REDDY, Consultant Hematopathologist, DHA License: 61713011

⚠️ Do not discontinue or modify any prescribed medication without direct instruction from your treating physician.

Safety Exclusion Criteria & Red Flags

Patients with acute, uncontrolled bleeding disorders or severe thrombocytopenia (platelets <20×10⁹/L) may require medical optimisation before bone marrow aspiration.
Severe local infection at the intended sampling site is an absolute contraindication for elective marrow aspiration.
Seek immediate emergency care if you experience sudden high fever (>38.5°C), uncontrolled bleeding, rapid swelling of lymph nodes, or severe bone pain unrelieved by rest.

Patient FAQ & Clinical Guidance

1. What does the ALL Panel with FISH detect, and why is it ordered?

This comprehensive genetic directly identifies chromosomal abnormalities and gene fusions—BCR/ABL, TEL/AML1, MLL, and E2A rearrangements—that define high‑risk acute lymphoblastic leukemia subtypes and guide targeted therapies. (يحدد هذا الفحص الجيني الشامل التشوهات الصبغية والاندماجات الجينية الحرجة التي تُصنف سرطان الدم الليمفاوي الحاد إلى أنماط عالية الخطورة وتوجه العلاجات الموجهة.)

2. How should I prepare for the sample collection, and is it painful?

Our mobile phlebotomist follows strict DHA protocols: bone marrow aspiration is performed under local anaesthesia, with mild pressure sensation but controlled discomfort; peripheral blood collection is a simple venipuncture. (يقوم أخصائي السحب لدينا بإجراء سحب نخاع العظم تحت تخدير موضعي وفق بروتوكولات هيئة الصحة بدبي، مع إحساس بسيط بالضغط؛ أما سحب الدم المحيطي فهو وخز وريدي بسيط.)

3. When will I receive the results and who will explain them?

The full cytogenetics and FISH report is available within 10 working days, and a consultant hematologist will provide a dedicated telephonic explanation of your results, linking the findings to your treatment plan. (يتوفر التقرير الكامل خلال 10 أيام عمل، ويقوم استشاري أمراض الدم بتفسير النتائج هاتفيًا وربطها بخطتك العلاجية.)

All services comply with Federal Decree-Law No. 41 of 2024 (Art. 87), the CDS Law 2026 (minors’ data protection), and the UAE Personal Data Protection Law (PDPL). Your genetic data is processed exclusively within UAE‑licensed servers under the highest confidentiality standards.

Laboratory certification: ISO 9001:2015 (Cert: INT/EGQ/2509DA/3139) | MOHAP Facility License: 9834453 | DHA‑regulated reporting.

For further clinical assistance or insurance verification, contact WhatsApp: +971 54 548 8731. Home collection available daily from 8 AM to 11 PM.

دعم ثنائي اللغة متاح